Targeting KRAS in Pancreatic Cancer

Pancreatic cancer is mainly driven by mutations in the KRAS oncogene. While this cancer has shown remarkable therapy resistance, new approaches to inhibit mutated KRAS, KRAS activators and effectors show promise in breaking this therapeutic deadlock. Here, we review these innovations in therapies that target RAS signaling in pancreatic cancer from a clinical point of view. A number of promising approaches are currently in clinical trials or in clinical development. We focus on small-molecule drugs but also discuss immunotherapies and tumor vaccines.

[1]  He Huang,et al.  Novel cellular immunotherapies for hematological malignancies: recent updates from the 2021 ASH annual meeting , 2022, Experimental Hematology & Oncology.

[2]  A. Dingemans,et al.  LBA10 Sotorasib versus docetaxel for previously treated non-small cell lung cancer with KRAS G12C mutation: CodeBreaK 200 phase III study , 2022, Annals of Oncology.

[3]  Kwok-Kin Wong,et al.  The current state of the art and future trends in RAS-targeted cancer therapies , 2022, Nature Reviews Clinical Oncology.

[4]  Mallika Singh,et al.  Abstract 3597: Direct targeting of KRASG12X mutant cancers with RMC-6236, a first-in-class, RAS-selective, orally bioavailable, tri-complex RASMULTI(ON) inhibitor , 2022, Cancer Research.

[5]  K. Haigis,et al.  Classification of KRAS-Activating Mutations and the Implications for Therapeutic Intervention. , 2022, Cancer discovery.

[6]  T. Burns,et al.  First data for sotorasib in patients with pancreatic cancer with KRAS p.G12C mutation: A phase I/II study evaluating efficacy and safety , 2022, Journal of Clinical Oncology.

[7]  J. Christensen,et al.  KRYSTAL-1: Updated activity and safety of adagrasib (MRTX849) in patients (Pts) with unresectable or metastatic pancreatic cancer (PDAC) and other gastrointestinal (GI) tumors harboring a KRASG12C mutation. , 2022, Journal of Clinical Oncology.

[8]  N. Kraut,et al.  Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants , 2022, Cancer discovery.

[9]  J. Blake,et al.  Identification of MRTX1133, a Noncovalent, Potent, and Selective KRASG12D Inhibitor. , 2021, Journal of medicinal chemistry.

[10]  M. T. Beck,et al.  KRAS is vulnerable to reversible switch-II pocket engagement in cells , 2021, bioRxiv.

[11]  M. J. Chalmers,et al.  Abstract 1259: Preclinical characterization of LY3537982, a novel, highly selective and potent KRAS-G12C inhibitor , 2021, Experimental and Molecular Therapeutics.

[12]  P. Jänne,et al.  Acquired Resistance to KRASG12C Inhibition in Cancer. , 2021, The New England journal of medicine.

[13]  R. Govindan,et al.  Sotorasib for Lung Cancers with KRAS p.G12C Mutation. , 2021, The New England journal of medicine.

[14]  N. Kraut,et al.  Targeting Son of Sevenless 1: The pacemaker of KRAS. , 2021, Current opinion in chemical biology.

[15]  M. V. Vander Heiden,et al.  The Metabolic Landscape of RAS-Driven Cancers from biology to therapy , 2021, Nature Cancer.

[16]  C. Kiel,et al.  The Ins and Outs of RAS Effector Complexes , 2021, Biomolecules.

[17]  J. Smaill,et al.  Small-Molecule Inhibitors Directly Targeting KRAS as Anticancer Therapeutics. , 2020, Journal of medicinal chemistry.

[18]  G. Fernandes,et al.  Trametinib and Hydroxychloroquine (HCQ) Combination Treatment in KRAS-Mutated Advanced Pancreatic Adenocarcinoma: Detailed Description of Two Cases , 2020, Journal of Gastrointestinal Cancer.

[19]  J. Johnston,et al.  A nanoparticle vaccine that targets neoantigen peptides to lymphoid tissues elicits robust antitumor T cell responses , 2020, NPJ vaccines.

[20]  T. Brummer,et al.  Immune modulatory effects of oncogenic KRAS in cancer , 2020, Nature Communications.

[21]  P. Hammerman,et al.  Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling , 2020, Clinical Cancer Research.

[22]  S. Gottschalk,et al.  CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality? , 2020, Molecular therapy : the journal of the American Society of Gene Therapy.

[23]  L. Buday,et al.  Novel regulation of Ras proteins by direct tyrosine phosphorylation and dephosphorylation , 2020, Cancer and Metastasis Reviews.

[24]  R. Kortum,et al.  Marked synergy by vertical inhibition of EGFR signaling in NSCLC spheroids shows SOS1 is a therapeutic target in EGFR-mutated cancer , 2020, eLife.

[25]  D. Unutmaz,et al.  Mechanisms of T-Cell Exhaustion in Pancreatic Cancer , 2020, Cancers.

[26]  F. McCormick,et al.  RAS-targeted therapies: is the undruggable drugged? , 2020, Nature Reviews Drug Discovery.

[27]  J. Blake,et al.  Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer , 2020 .

[28]  Raghu Kalluri,et al.  The biology, function, and biomedical applications of exosomes , 2020, Science.

[29]  N. Chen,et al.  Discovery of a covalent inhibitor of KRASG12C (AMG 510) for the treatment of solid tumors. , 2019, Journal of medicinal chemistry.

[30]  J. Desai,et al.  The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity , 2019, Nature.

[31]  D. V. Von Hoff,et al.  Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer: A Phase 2 Randomized Clinical Trial. , 2019, JAMA oncology.

[32]  J. Ross,et al.  Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers. , 2019, Gastroenterology.

[33]  Yijun Wang,et al.  Targeting the untargetable KRAS in cancer therapy , 2019, Acta pharmaceutica Sinica. B.

[34]  J. Yap,et al.  Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers , 2019, Nature Medicine.

[35]  H. Kocher,et al.  Pancreatic Cancer , 2019, Methods in Molecular Biology.

[36]  Oleksii S. Rukhlenko,et al.  Dissecting RAF Inhibitor Resistance by Structure-based Modeling Reveals Ways to Overcome Oncogenic RAS Signaling. , 2018, Cell systems.

[37]  P. Zarrinkar,et al.  Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor , 2018, Cell.

[38]  Kevan M. Shokat,et al.  Ras Binder Induces a Modified Switch-II Pocket in GTP and GDP States. , 2017, Cell chemical biology.

[39]  E. Collisson,et al.  Advances in the Genetics and Biology of Pancreatic Cancer. , 2017, Cancer journal.

[40]  Steven J. M. Jones,et al.  Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. , 2017, Cancer cell.

[41]  Ludmila V. Danilova,et al.  Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade , 2017, Science.

[42]  P. Lyne,et al.  Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS , 2017, Science Translational Medicine.

[43]  P. Jänne,et al.  Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non–Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial , 2017, JAMA.

[44]  Raghu Kalluri,et al.  Exosomes Facilitate Therapeutic Targeting of Oncogenic Kras in Pancreatic Cancer , 2017, Nature.

[45]  P. Philip,et al.  Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial , 2017, JAMA oncology.

[46]  J. Gartner,et al.  T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer. , 2016, The New England journal of medicine.

[47]  Oleksii S. Rukhlenko,et al.  MAPK kinase signalling dynamics regulate cell fate decisions and drug resistance. , 2016, Current opinion in structural biology.

[48]  Ryan L. Kelly,et al.  Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses , 2016, Nature Medicine.

[49]  S. Steinberg,et al.  Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  Yi Liu,et al.  Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State. , 2016, Cancer discovery.

[51]  Walter Kolch,et al.  Phosphorylation of RAF Kinase Dimers Drives Conformational Changes that Facilitate Transactivation , 2015, Angewandte Chemie.

[52]  D. Torigian,et al.  Safety and antitumor activity of chimeric antigen receptor modified T cells in patients with chemotherapy refractory metastatic pancreatic cancer. , 2015 .

[53]  R. Eliakim,et al.  RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients , 2015, Oncotarget.

[54]  S. Fröhling,et al.  Comparative analysis of KRAS codon 12, 13, 18, 61, and 117 mutations using human MCF10A isogenic cell lines , 2015, Scientific Reports.

[55]  M. Kris,et al.  Phase II study of the GI-4000 KRAS vaccine after curative therapy in patients with stage I-III lung adenocarcinoma harboring a KRAS G12C, G12D, or G12V mutation. , 2014, Clinical lung cancer.

[56]  Ji Luo,et al.  Development of siRNA payloads to target KRAS-mutant cancer. , 2014, Cancer discovery.

[57]  Joon-Oh Park,et al.  A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas. , 2014, European journal of cancer.

[58]  Gregory L. Szeto,et al.  Structure-based programming of lymph-node targeting in molecular vaccines , 2014, Nature.

[59]  Roland Seifert,et al.  Faculty Opinions recommendation of K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. , 2013 .

[60]  Kevan M. Shokat,et al.  K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions , 2013, Nature.

[61]  Lincoln D. Stein,et al.  Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes , 2012, Nature.

[62]  H. Abken,et al.  T cells that target carcinoembryonic antigen eradicate orthotopic pancreatic carcinomas without inducing autoimmune colitis in mice. , 2012, Gastroenterology.

[63]  Derek S. Chan,et al.  The Pancreas Cancer Microenvironment , 2012, Clinical Cancer Research.

[64]  D. Bar-Sagi,et al.  Sos-mediated cross activation of wild-type Ras by oncogenic Ras is essential for tumorigenesis , 2012, Nature Communications.

[65]  T. Ciuleanu,et al.  A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy , 2012, Investigational New Drugs.

[66]  Pierre Michel,et al.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. , 2011, The New England journal of medicine.

[67]  S. Rosenberg,et al.  Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma , 2010, Journal of immunotherapy.

[68]  P. Kantoff,et al.  Sipuleucel-T immunotherapy for castration-resistant prostate cancer. , 2010, The New England journal of medicine.

[69]  R. Bernards,et al.  Stable suppression of tumorigenicity by virus-mediated RNA interference. , 2002, Cancer cell.